VRCA
Verrica Pharmaceuticals Inc.
Price Chart
Latest Quote
$5.59
+0.03 (+0.54%)
Current Price
| Previous Close | $5.56 |
| Open | $5.44 |
| Day High | $5.65 |
| Day Low | $5.12 |
| Volume | 48,863 |
Stock Information
| Shares Outstanding | 17.18M |
| Total Debt | $1.44M |
| Cash Equivalents | $20.60M |
| Revenue | $37.16M |
| Net Income | $-17.83M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $96.03M |
| EPS (TTM) | $-1.10 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $76.87M |
| Sales | $37.16M |
| Income | $-17.83M |
| Book/sh | $0.94 |
| Cash/sh | $1.20 |
| Employees | 76 |
Financial Ratios
| Quick Ratio | 1.75 |
| Current Ratio | 2.10 |
| Debt/Eq | 8.98 |
Returns & Margins
| ROA | -20.88% |
| Gross Margin | 61.45% |
| Operating Margin | -193.41% |
| Profit Margin | -47.97% |
Ownership
| Insider Ownership | 48.75% |
| Institutional Ownership | 27.87% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.50 |
| P/S | 2.58 |
| P/B | 5.98 |
Analyst Data
| Recommendation | none |
| Target Price | $15.54 |
Technical Indicators
| SMA20 | $6.04 |
| SMA50 | $6.22 |
| SMA200 | $6.04 |
| RSI | 27.84 |
| ATR | 0.4715 |
| Shares Float | 7.90M |
| Short Float | 3.68% |
| Short Ratio | 7.20 |
| Volatility | 1.48 |
| Rel Volume | 1.18 |
Performance History
| Week | -10.70% |
| Month | -6.83% |
| Quarter | -9.98% |
| 6 Months | -29.69% |
| YTD | -32.65% |
| Year | -33.37% |
| 3 Years | -91.78% |
| 5 Years | -94.61% |
| 10 Years | -96.81% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $5.59 | 48,863 |
| 2026-07-16 | $5.56 | 23,600 |
| 2026-07-15 | $5.66 | 30,900 |
| 2026-07-14 | $5.93 | 10,700 |
| 2026-07-13 | $5.92 | 13,800 |
| 2026-07-10 | $6.26 | 14,100 |
| 2026-07-09 | $6.53 | 35,300 |
| 2026-07-08 | $6.62 | 75,200 |
| 2026-07-07 | $6.07 | 10,700 |
| 2026-07-06 | $6.13 | 40,400 |
| 2026-07-02 | $6.14 | 22,900 |
| 2026-07-01 | $5.94 | 35,400 |
| 2026-06-30 | $6.12 | 34,500 |
| 2026-06-29 | $6.50 | 66,700 |
| 2026-06-26 | $6.84 | 113,900 |
| 2026-06-25 | $6.21 | 62,500 |
| 2026-06-24 | $5.85 | 24,100 |
| 2026-06-23 | $5.65 | 34,300 |
| 2026-06-22 | $5.64 | 105,100 |
| 2026-06-18 | $5.63 | 26,800 |
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
đ° Latest News
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
Benzinga âĸ 2026-05-13T09:16:44Z
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
GuruFocus.com âĸ 2026-05-13T05:01:37ZVerrica Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T03:07:44Z
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-12T21:15:02Z
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-07T19:15:01Z
NanoViricidesâ Measles Treatment Granted Orphan Drug Designation by FDA
Exec Edge âĸ 2026-05-06T12:35:33Z
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-05T21:15:04Z
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
GuruFocus.com âĸ 2026-03-11T19:01:43ZVerrica Pharmaceuticals Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-11T17:01:40Z
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why
Zacks âĸ 2026-02-02T17:00:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,441,000 | $2,740,000 | $746,000 | $725,000 |
| Cost Of Revenue | $3,441,000 | $2,740,000 | $746,000 | $725,000 |
| Total Revenue | $35,577,000 | $7,566,000 | $5,124,000 | $9,032,000 |
| Operating Revenue | $35,577,000 | $7,566,000 | $5,124,000 | $9,032,000 |
| Expenses | ||||
| Interest Expense | $7,742,000 | $9,412,000 | $3,962,000 | $2,172,000 |
| Total Expenses | $47,516,000 | $73,402,000 | $68,346,000 | $30,328,000 |
| Other Income Expense | $866,000 | $-2,748,000 | $-2,551,000 | $-1,495,000 |
| Other Non Operating Income Expenses | $-3,000 | $-17,000 | $-14,000 | $-58,000 |
| Net Non Operating Interest Income Expense | $-6,813,000 | $-7,995,000 | $-1,222,000 | $-1,696,000 |
| Interest Expense Non Operating | $7,742,000 | $9,412,000 | $3,962,000 | $2,172,000 |
| Operating Expense | $44,075,000 | $70,662,000 | $67,600,000 | $29,603,000 |
| General And Administrative Expense | - | - | - | $17,405,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Net Interest Income | $-6,813,000 | $-7,995,000 | $-1,222,000 | $-1,696,000 |
| Interest Income | $929,000 | $1,417,000 | $2,740,000 | $476,000 |
| Normalized Income | $-18,755,000 | $-73,848,000 | $-64,458,000 | $-23,050,000 |
| Net Income From Continuing And Discontinued Operation | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Total Operating Income As Reported | $-12,185,000 | $-65,919,000 | $-65,759,000 | $-21,296,000 |
| Net Income Common Stockholders | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Net Income | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Net Income Including Noncontrolling Interests | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Net Income Continuous Operations | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Pretax Income | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Special Income Charges | $-1,779,000 | $-83,000 | $-2,537,000 | $-1,437,000 |
| Interest Income Non Operating | $929,000 | $1,417,000 | $2,740,000 | $476,000 |
| Operating Income | $-11,939,000 | $-65,836,000 | $-63,222,000 | $-21,296,000 |
| Gross Profit | $32,136,000 | $4,826,000 | $4,378,000 | $8,307,000 |
| Per Share | ||||
| Diluted EPS | $-1.68 | $-14.80 | $-14.80 | $-7.20 |
| Basic EPS | $-1.68 | $-14.80 | $-14.80 | $-7.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-10,232,000 | $-63,167,000 | $-59,660,000 | $-20,160,000 |
| Total Unusual Items | $869,000 | $-2,731,000 | $-2,537,000 | $-1,437,000 |
| Total Unusual Items Excluding Goodwill | $869,000 | $-2,731,000 | $-2,537,000 | $-1,437,000 |
| Reconciled Depreciation | $781,000 | $1,269,000 | $836,000 | $718,000 |
| EBITDA (Bullshit earnings) | $-9,363,000 | $-65,898,000 | $-62,197,000 | $-21,597,000 |
| EBIT | $-10,144,000 | $-67,167,000 | $-63,033,000 | $-22,315,000 |
| Diluted Average Shares | $10,652,367 | $5,180,822 | $4,534,245 | $3,416,343 |
| Basic Average Shares | $10,652,367 | $5,180,822 | $4,534,245 | $3,416,343 |
| Diluted NI Availto Com Stockholders | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Gain On Sale Of Ppe | $-246,000 | $-83,000 | $-2,537,000 | $0 |
| Other Special Charges | $1,533,000 | - | - | $1,437,000 |
| Gain On Sale Of Security | $2,648,000 | $-2,648,000 | - | - |
| Research And Development | $8,855,000 | $11,840,000 | $20,295,000 | $12,198,000 |
| Selling General And Administration | $35,220,000 | $58,822,000 | $47,305,000 | $17,405,000 |
| Other Gand A | - | - | - | $17,405,000 |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $24,743,000 | $-9,860,000 | $19,763,000 | $40,033,000 |
| Total Assets | $47,131,000 | $54,134,000 | $81,597,000 | $44,721,000 |
| Total Non Current Assets | $4,592,000 | $2,955,000 | $4,067,000 | $5,606,000 |
| Other Non Current Assets | $376,000 | $376,000 | $452,000 | $276,000 |
| Non Current Deferred Assets | $2,354,000 | $0 | - | - |
| Current Assets | $42,539,000 | $51,179,000 | $77,530,000 | $39,115,000 |
| Other Current Assets | $2,801,000 | $2,310,000 | $2,545,000 | $4,355,000 |
| Current Deferred Assets | $1,958,000 | $0 | - | - |
| Inventory | $2,236,000 | $2,463,000 | $1,022,000 | $0 |
| Receivables | $5,397,000 | $77,000 | $4,416,000 | $487,000 |
| Other Receivables | $137,000 | $29,000 | $168,000 | $99,000 |
| Accounts Receivable | $5,260,000 | $48,000 | $4,248,000 | $388,000 |
| Cash Cash Equivalents And Short Term Investments | $30,147,000 | $46,329,000 | $69,547,000 | $34,273,000 |
| Cash And Cash Equivalents | $30,147,000 | $46,329,000 | $69,547,000 | $34,273,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,631,000 | $45,939,000 | $45,510,000 | $1,526,000 |
| Long Term Debt And Capital Lease Obligation | $885,000 | $32,334,000 | $44,810,000 | $1,229,000 |
| Current Debt And Capital Lease Obligation | $746,000 | $13,605,000 | $700,000 | $297,000 |
| Long Term Debt | - | $30,983,000 | $42,874,000 | - |
| Current Debt | - | $12,938,000 | - | - |
| Other Current Borrowings | - | $12,938,000 | - | - |
| Net Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $22,388,000 | $63,994,000 | $61,834,000 | $4,688,000 |
| Total Non Current Liabilities Net Minority Interest | $5,951,000 | $34,982,000 | $44,810,000 | $1,229,000 |
| Other Non Current Liabilities | $5,066,000 | - | - | - |
| Derivative Product Liabilities | $0 | $2,648,000 | $0 | - |
| Current Liabilities | $16,437,000 | $29,012,000 | $17,024,000 | $3,459,000 |
| Other Current Liabilities | $119,000 | $105,000 | $244,000 | - |
| Current Deferred Liabilities | $782,000 | $0 | - | - |
| Payables And Accrued Expenses | $4,465,000 | $3,813,000 | $7,285,000 | $1,763,000 |
| Payables | $2,072,000 | $1,896,000 | $2,464,000 | $507,000 |
| Accounts Payable | $2,072,000 | $1,896,000 | $2,464,000 | $507,000 |
| Interest Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $24,743,000 | $-9,860,000 | $19,763,000 | $40,033,000 |
| Total Equity Gross Minority Interest | $24,743,000 | $-9,860,000 | $19,763,000 | $40,033,000 |
| Stockholders Equity | $24,743,000 | $-9,860,000 | $19,763,000 | $40,033,000 |
| Retained Earnings | $-324,913,000 | $-307,027,000 | $-230,448,000 | $-163,453,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | - | $0 |
| Other Equity Adjustments | - | - | - | - |
| Other | ||||
| Treasury Shares Number | $10,514 | $10,514 | $10,514 | $10,514 |
| Ordinary Shares Number | $17,178,786 | $9,177,999 | $4,241,355 | $4,109,405 |
| Share Issued | $17,189,300 | $9,188,513 | $4,251,869 | $4,119,919 |
| Tangible Book Value | $24,743,000 | $-9,860,000 | $19,763,000 | $40,033,000 |
| Invested Capital | $24,743,000 | $34,061,000 | $62,637,000 | $40,033,000 |
| Working Capital | $26,102,000 | $22,167,000 | $60,506,000 | $35,656,000 |
| Capital Lease Obligations | $1,631,000 | $2,018,000 | $2,636,000 | $1,526,000 |
| Total Capitalization | $24,743,000 | $21,123,000 | $62,637,000 | $40,033,000 |
| Treasury Stock | $0 | $0 | $0 | $0 |
| Additional Paid In Capital | $349,654,000 | $297,166,000 | $250,207,000 | $203,482,000 |
| Capital Stock | $2,000 | $1,000 | $4,000 | $4,000 |
| Common Stock | $2,000 | $1,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $885,000 | $1,351,000 | $1,936,000 | $1,229,000 |
| Current Deferred Revenue | $782,000 | $0 | - | - |
| Current Capital Lease Obligation | $746,000 | $667,000 | $700,000 | $297,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,763,000 | $1,173,000 | $3,438,000 | $1,399,000 |
| Current Provisions | $8,562,000 | $10,316,000 | $5,357,000 | - |
| Current Accrued Expenses | $2,393,000 | $1,917,000 | $4,821,000 | $1,256,000 |
| Net PPE | $1,862,000 | $2,579,000 | $3,615,000 | $5,330,000 |
| Accumulated Depreciation | $-1,050,000 | $-1,258,000 | $-1,174,000 | $-699,000 |
| Gross PPE | $2,912,000 | $3,837,000 | $4,789,000 | $6,029,000 |
| Leases | $54,000 | $54,000 | $54,000 | $54,000 |
| Other Properties | $1,113,000 | $1,154,000 | $1,405,000 | - |
| Machinery Furniture Equipment | $1,205,000 | $1,793,000 | $2,172,000 | $1,996,000 |
| Buildings And Improvements | $540,000 | $836,000 | $1,158,000 | $1,443,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $478,000 | $717,000 | $115,000 | $0 |
| Work In Process | $784,000 | $664,000 | $487,000 | $0 |
| Raw Materials | $974,000 | $1,082,000 | $420,000 | $0 |
| Construction In Progress | - | - | $0 | $2,536,000 |
| Other Short Term Investments | - | - | - | $0 |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,627,000 | $-60,954,000 | $-38,939,000 | $-18,952,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-17,627,000 | $-60,927,000 | $-38,577,000 | $-18,650,000 |
| Cash Flow From Continuing Operating Activities | $-17,627,000 | $-60,927,000 | $-38,577,000 | $-18,650,000 |
| Operating Gains Losses | $-869,000 | $2,731,000 | $2,537,000 | $1,437,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-19,000 | $-362,000 | $54,041,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-19,000 | $-362,000 | $54,041,000 |
| Capital Expenditure | - | $-27,000 | $-362,000 | $-302,000 |
| Net Other Investing Changes | - | - | - | $-180,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $50,067,000 | $42,501,000 | $30,300,000 | $26,901,000 |
| Financing Cash Flow | $1,445,000 | $37,728,000 | $74,213,000 | $-16,870,000 |
| Cash Flow From Continuing Financing Activities | $1,445,000 | $37,728,000 | $74,212,000 | $-16,870,000 |
| Net Other Financing Charges | $-420,000 | $-4,004,000 | $-176,000 | $-17,000 |
| Net Common Stock Issuance | $50,067,000 | $42,501,000 | $30,300,000 | $26,901,000 |
| Common Stock Issuance | $50,067,000 | $42,501,000 | $30,300,000 | $26,901,000 |
| Other | ||||
| Repayment Of Debt | $-48,202,000 | $-924,000 | $-23,000 | $-43,754,000 |
| Issuance Of Debt | $0 | $0 | $44,105,000 | $0 |
| Interest Paid Supplemental Data | $5,171,000 | $7,225,000 | $3,152,000 | $1,789,000 |
| End Cash Position | $30,147,000 | $46,329,000 | $69,547,000 | $34,273,000 |
| Beginning Cash Position | $46,329,000 | $69,547,000 | $34,273,000 | $15,752,000 |
| Changes In Cash | $-16,182,000 | $-23,218,000 | $35,274,000 | $18,521,000 |
| Proceeds From Stock Option Exercised | $0 | $155,000 | $7,000 | $0 |
| Net Issuance Payments Of Debt | $-48,202,000 | $-924,000 | $44,082,000 | $-43,754,000 |
| Net Long Term Debt Issuance | $-48,202,000 | $-924,000 | $44,082,000 | $-43,754,000 |
| Long Term Debt Payments | $-48,202,000 | $-924,000 | $-23,000 | $-43,754,000 |
| Long Term Debt Issuance | $0 | $0 | $44,105,000 | $0 |
| Net PPE Purchase And Sale | $0 | $-19,000 | $-362,000 | $-302,000 |
| Sale Of PPE | $0 | $8,000 | $0 | - |
| Purchase Of PPE | $0 | $-27,000 | $-362,000 | $-302,000 |
| Change In Working Capital | $-6,252,000 | $2,027,000 | $9,859,000 | $-1,800,000 |
| Change In Other Working Capital | $782,000 | - | - | - |
| Change In Other Current Liabilities | $-315,000 | $-322,000 | $-291,000 | $-264,000 |
| Change In Payables And Accrued Expense | $-1,135,000 | $-862,000 | $13,492,000 | $-593,000 |
| Change In Accrued Expense | $-1,311,000 | $-294,000 | $11,291,000 | $-255,000 |
| Change In Payable | $176,000 | $-568,000 | $2,201,000 | $-338,000 |
| Change In Account Payable | $176,000 | $-568,000 | $2,201,000 | $-338,000 |
| Change In Prepaid Assets | $-264,000 | $-1,128,000 | $587,000 | $-456,000 |
| Change In Receivables | $-5,320,000 | $4,339,000 | $-3,929,000 | $-487,000 |
| Changes In Account Receivables | $-5,212,000 | $4,200,000 | $-3,860,000 | $0 |
| Other Non Cash Items | $3,281,000 | $2,206,000 | $810,000 | $389,000 |
| Stock Based Compensation | $3,318,000 | $7,164,000 | $14,376,000 | $4,985,000 |
| Asset Impairment Charge | $0 | $255,000 | $0 | - |
| Depreciation Amortization Depletion | $781,000 | $1,269,000 | $836,000 | $718,000 |
| Depreciation And Amortization | $781,000 | $1,269,000 | $836,000 | $718,000 |
| Depreciation | $781,000 | $1,269,000 | $836,000 | $718,000 |
| Gain Loss On Investment Securities | $-2,648,000 | $2,648,000 | - | - |
| Gain Loss On Sale Of PPE | $246,000 | $83,000 | $2,537,000 | $0 |
| Net Income From Continuing Operations | $-17,886,000 | $-76,579,000 | $-66,995,000 | $-24,487,000 |
| Net Investment Purchase And Sale | - | - | $0 | $54,343,000 |
| Sale Of Investment | - | - | $0 | $59,008,000 |
| Purchase Of Investment | - | - | $0 | $-4,665,000 |
| Amortization Of Securities | - | - | $0 | $108,000 |
| Net Short Term Debt Issuance | - | - | - | $-43,750,000 |
| Short Term Debt Payments | - | - | - | $-43,750,000 |
| Short Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-07-17